



WETENSCHAPPELIJK INSTITUUT
VOLKSGEZONDHEID
INSTITUT SCIENTIFIQUE
DE SANTÉ PUBLIQUE

Laboratory-Acquired Infections in Belgium (2007-2012)

An online Survey

**Scientific Institute of Public Health
Biosafety & Biotechnology Unit (SBB)
Nicolas Willemarck, PhD**

Rue Juliette Wytsmanstraat 14 | 1050 Brussels | Belgium
T +32 2 642 52 93 | F +32 2 642 52 92 | email: contained.use@wiv-isp.be | www.wiv-isp.be

.be

Introduction

Aim of the survey

2

▶ Gathering information on **bio-incidents** and **LAIs** in Belgian micro-biological laboratories to gain insight into possible underlying causes so as to provide the biosafety officer with tools which can enhance biological safety.

▶ **Laboratory-Acquired Infections (LAIs)**

« All direct or indirect human infections with or without the onset of symptoms following exposure to pathogenic organisms in a micro-biological laboratory »

▶ **Bio-incidents**

« All irregularities that occur while handling GMOs or pathogenic organisms »

Belgian LAI Survey 2007-2012

4

- ▶ **2012:** Online LAI survey in Flanders organized by SBB at the request of the Flemish Agency for Care and Health, Department Public health and Surveillance.
- ▶ **2013:** Extended over whole Belgium (Flemish, Walloon and Brussels-capital region)

**Survey 1. Biosafety officer, prevention officer,
occupational health practitioner**

>> 213 institutions invited

>> Two types of questionnaires:

Survey 2. Personnel (survey 2)

>> 26 institutions invited (873 employees)

Belgian LAI Survey 2007-2012

5

- ▶ **Tool:** Limesurvey 2.0, free online web survey tool with an automatic invitation, reminder and confirmation e-mail system



- ▶ **Anonymous**

Invitation addressed to the biosafety officer provided a web link (URL) and a unique token which granted access to the survey

- ▶ **In Dutch, French and English**


- ▶ **~50 questions and sub questions**

Single-answer questions, multiple question and open questions
Most of the question were mandatory

Participation

Belgian LAI Survey 2007-2012

6



Laboratory-Acquired Infections in Belgium (2007-2012)


An online Survey

please peruse the LAI reports at your convenience online www.biosafety.be


Belgian LAI Survey 2007-2012

7


Containment levels available in the institutions survey 1



Containment levels available in the institutions survey 2



Containment levels in recent authorizations (n=559)



* Other: HR1 , LS1 , L2/BK, L2/Q, L3/BSE , G1-2/Q

LEGENDS: L = laboratory ; A = Animal facility; G = Green houses; HR = hospital room ; LS = large scale


Participation Belgian LAI Survey 2007-2012

8

▶ Participation rate in different sectors

	Survey 1 (N= 213)	Survey 2 (N = 873)
(Bio)medical (Human)	75%	60%
Veterinary (Animals)	9%	39%
Plant research	15%	1%

▶ Different types of activities



Participation

Belgian LAI Survey 2007-2012

9

► **Conclusion:**

- The distribution pattern of the type of installations in survey 1 is similar to the requested containment levels in recent authorizations
- Similar patterns are observed in survey 2 for the types of activities and installations
- All types of sectors (except plant research) and activities are represented

>>> REPRESENTATIVE GROUP of participants in both surveys

Belgian LAI Survey 2007-2012

10


Organism [max. number of cases _ %]	Risk class ¹	Where did the infection happen?					Possible transmission route			
		L1	L2	L3	A2	Unknown	Inhalation	Parenteral inoculation	Ingestion / contact	Unknown
<i>Salmonella bacteria</i> (*) [N =20_25%]	2-3	5%	45%	5%		45%	8%		8%	85%
<i>Mycobacterium tuberculosis complex</i> (*) [N = 15_19%]	3		33%	20%		47%			3%	97%
<i>Brucella bacteria</i> (*) [N = 10_13%]	3	10%	30%	40%		20%	30%	10%	10%	50%
<i>Trypanosoma brucei gambiense</i> [N = 6_8%]	2		67%		33%			100%		
Dermatophyte (<i>Microsporium canis</i> & <i>Trichophyton verrucosum</i>) [N = 5_6%]	2		20%		40%	40%				100%
<i>Shigella bacteria</i> (‡) [N =4_5%]	2-3		100%							100%
<i>Coxiella burnetii</i> (*) [N = 3_4%]	2					100%				100%
<i>Mycoplasma</i> [N = 2_2%]	2		100%				25%		25%	50%
<i>Herpes virus</i> [N =2_2%]	2		100%				50%		50%	
Hepatitis B virus [N =2_2%]	3					100%		100%		
<i>Campylobacter</i> (‡) [N =1_1%]	2		100%							100%
BCG (<i>Bacillus Calmette Guérin</i>) [N =1_1%]	2			100%						100%
Parvovirus B19 [N =1_1%]	2		100%							100%
Avian Influenza (*) [N =1_1%]	2		100%							100%
HIV [N =1_1%]	3		100%					100%		
<i>Toxoplasma gondii</i> [N =1_1%]	2			100%				100%		
<i>Bartonella bacteria</i> [N =1_1%]	2-3			100%						100%
<i>Rabies virus</i> (*) [N =1_1%]	3					100%		100%		
Recombinant viral vector [N =1_1%]	2-3					100%				100%
<i>Rubella virus</i> [N =1_1%]	2		100%							100%
<i>Listeria bacteria</i> [N =1_1%]	2					100%				100%

¹ Risk classes for human as based on the Belgian risk classifications of micro-organisms, <http://www.biosafety.be/RA/Class/ClassBEL.html>; * notifiable infectious disease (; ⁵ only in case of collective outbreak)

Belgian LAI Survey 2007-2012

11

Organism	Risk class ¹	Max number of cases (%)
<i>Salmonella</i> bacteria (*)	2-3	20 (25%)
<i>Mycobacterium tuberculosis</i> complex (*)	3	15 (19%)
<i>Brucella</i> bacteria (*)	3	10 (13%)
<i>Trypanosoma brucei gambiense</i>	2	6 (8%)
Dermatophyte	2	5 (6%)
<i>Shigella</i> bacteria (♯)	2-3	4 (5%)
<i>Coxiella burnetii</i> (*)	2	3 (4%)
<i>Mycoplasma</i>	2	2 (2%)
Herpes virus	2	2 (2%)
Hepatitis B virus	3	2 (2%)
<i>Campylobacter</i> (♯)	2	1 (1%)
BCG (<i>Bacillus Calmette Guérin</i>)	2	1 (1%)
Parvovirus B19	2	1 (1%)
Avian Influenza (*)	2	1 (1%)
HIV	3	1 (1%)
<i>Toxoplasma gondii</i>	2	1 (1%)
<i>Bartonella</i> bacteria	2-3	1 (1%)
Rabies virus (*)	3	1 (1%)
Recombinant viral vector	2-3	1 (1%)
Rubella virus	2	1 (1%)
<i>Listeria</i> bacteria	2	1 (1%)




¹ Risk classes for human as based on the Belgian risk classifications of micro-organisms; * notifiable infectious disease (♯ only in case of collective outbreak / >2 cases)


Identified transmission routes

Belgian LAI Survey 2007-2012

Who was infected?




Where did the infection happen?




Belgian LAI Survey 2007-2012

In which context did the infection happen?




Type of incident involved in the infection?




Belgian LAI Survey 2007-2012

14

Was it transmitted to another person?



Is it proven that the infection is work related?



Days of disability (n=16)

